/TMDX
TMDX Stock - TransMedics Group, Inc.
Healthcare|Medical - DevicesNASDAQ
$127.67+5.45%
+$6.60 (+5.45%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).82
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.38
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.9%upside
Target: $147.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TMDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$126.39 – $128.95
TARGET (TP)$148.00
STOP LOSS$117.46
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.05
52W High$156.00
52W Low$55.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $441.54M | $241.62M | $93.46M | $30.26M | $25.64M |
| Gross Profit | $262.08M | $154.09M | $65.27M | $21.16M | $16.64M |
| Gross Margin | 59.4% | 63.8% | 69.8% | 69.9% | 64.9% |
| Operating Income | $37.50M | $-28,727,000 | $-31,437,000 | $-39,428,000 | $-26,384,000 |
| Net Income | $35.46M | $-25,028,000 | $-36,231,000 | $-44,215,000 | $-28,748,000 |
| Net Margin | 8.0% | -10.4% | -38.8% | -146.1% | -112.1% |
| EPS | $1.07 | $-0.77 | $-1.23 | $-1.60 | $-1.16 |
Company Overview
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
73%
Hold / Neutral
3
27%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish3 Neutral/Bearish
Price Targets
$133
Average Target
↑ 4.5% Upside
Now
$48
Low
$133
Average
$208
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 23rd 2025 | Needham | Upgrade | Buy | $148 |
| October 13th 2025 | Jefferies | Initiation | Buy | $145 |
| September 16th 2025 | Evercore ISI | Initiation | Outperform | $155 |
| September 4th 2025 | Stifel | Initiation | Hold | $115 |
| December 17th 2024 | JP Morgan | Downgrade | Neutral | $75← $116 |
| November 22nd 2024 | Needham | Downgrade | Hold | - |
| October 29th 2024 | Oppenheimer | Reiterated | Outperform | $125← $200 |
| October 29th 2024 | Needham | Reiterated | Buy | $109← $208 |
| September 24th 2024 | Robert W. Baird | Initiation | Outperform | $200 |
| August 21st 2024 | Needham | Initiation | Buy | $208 |
| June 6th 2024 | Cantor Fitzgerald | Initiation | Overweight | $161 |
| June 4th 2024 | Stephens | Initiation | Overweight | $151 |
| March 28th 2024 | Piper Sandler | Initiation | Overweight | $95 |
| July 19th 2023 | Robert W. Baird | Initiation | Outperform | - |
| August 2nd 2022 | JP Morgan | Upgrade | Overweight | $48 |
Earnings History & Surprises
TMDXBeat Rate
61%
Last 18 quarters
Avg Surprise
+105.0%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$0.66
Q4 2025
EPS Surprise History
Q1 24
+500.0%
$0.12vs$0.02
Q2 24
+974.9%
$0.35vs$0.03
Q3 24
+66.7%
$0.35vs$0.21
Q4 24
-58.6%
$0.12vs$0.29
Q1 25
-13.6%
$0.19vs$0.22
Q2 25
+141.4%
$0.70vs$0.29
Q3 25
+91.7%
$0.92vs$0.48
Q4 25
+78.4%
$0.66vs$0.37
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.41 | — | — | — |
Q4 2025 | Oct 29, 2025 | $0.37 | $0.66 | +78.4% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.48 | $0.92 | +91.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.29 | $0.70 | +141.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.22 | $0.19 | -13.6% | ✗ MISS |
Q4 2024 | Oct 28, 2024 | $0.29 | $0.12 | -58.6% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $0.21 | $0.35 | +66.7% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $0.03 | $0.35 | +974.9% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.02 | $0.12 | +500.0% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.15 | $-0.03 | +80.0% | ✓ BEAT |
Q2 2023 | May 1, 2023 | $-0.25 | $-0.08 | +68.0% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.28 | $-0.21 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.40 | $-0.25 | +37.5% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $-0.32 | $-0.41 | -28.1% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.32 | $-0.47 | -46.9% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.27 | $-0.39 | -44.4% | ✗ MISS |
Latest News
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $148
📈 PositiveBenzinga•Dec 17, 2025, 08:10 PM•Also:
Needham Maintains Buy on TransMedics Group, Raises Price Target to $166
📈 PositiveBenzinga•Dec 8, 2025, 12:12 PM
Morgan Stanley Maintains Equal-Weight on TransMedics Group, Raises Price Target to $135
📈 PositiveBenzinga•Dec 2, 2025, 06:01 PM
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
📈 PositiveBenzinga•Oct 30, 2025, 02:07 PM•Also:
TMDX stock has given up its prior loss. TransMedics Group shares were trading lower after the company reported mixed Q3 financial results.
➖ NeutralBenzinga•Oct 30, 2025, 02:07 PM
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
➖ NeutralBenzinga•Oct 30, 2025, 01:41 PM
TransMedics Group shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Oct 30, 2025, 10:37 AM
TransMedics Group shares are trading lower after the company reported mized Q3 financial results.
📉 NegativeBenzinga•Oct 29, 2025, 08:07 PM
TransMedics Group Raises FY2025 Sales Guidance from $585.000M-$605.000M to $595.000M-$605.000M vs $600.848M Est
📈 PositiveBenzinga•Oct 29, 2025, 08:07 PM
TransMedics Gr Q3 EPS $0.66 Beats $0.35 Estimate, Sales $143.823M Miss $145.256M Estimate
📈 PositiveBenzinga•Oct 29, 2025, 08:06 PM
TransMedics upgraded at Needham on strong US sales
📈 PositiveSeeking Alpha•Oct 23, 2025, 03:25 PM
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
📈 PositiveBenzinga•Oct 23, 2025, 10:45 AM
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
📈 PositiveBenzinga•Oct 14, 2025, 02:12 PM•Also:
Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145
📈 PositiveBenzinga•Oct 13, 2025, 11:43 AM•Also:
TransMedics Group Unit Acquires $14.5M Fixed-Wing Aircraft From Teaghlach Aviation; Expands Fleet To 22 For National Organ Transport Program
📈 PositiveBenzinga•Oct 6, 2025, 08:38 PM
Evercore ISI Group Initiates Coverage On TransMedics Group with Outperform Rating, Announces Price Target of $155
📈 PositiveBenzinga•Sep 16, 2025, 03:19 PM
Stifel Initiates Coverage On TransMedics Group with Hold Rating, Announces Price Target of $115
➖ NeutralBenzinga•Sep 4, 2025, 04:02 PM•Also:
Needham Reiterates Hold on TransMedics Groupto Hold
➖ NeutralBenzinga•Aug 25, 2025, 02:52 PM
TransMedics rises after CEO buys company stock
📈 PositiveSeeking Alpha•Aug 11, 2025, 04:19 PM
TransMedics rises as FDA greenlights OCS heart trial
📈 PositiveSeeking Alpha•Aug 4, 2025, 06:07 PM
Frequently Asked Questions about TMDX
What is TMDX's current stock price?
TransMedics Group, Inc. (TMDX) is currently trading at $127.67 per share. The stock has moved +5.45% today.
What is the analyst price target for TMDX?
The average analyst price target for TMDX is $148.00, based on 1 analyst.
What sector is TransMedics Group, Inc. in?
TransMedics Group, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is TMDX's market cap?
TransMedics Group, Inc. has a market capitalization of $4.36 billion, making it a mid-cap company.
Does TMDX pay dividends?
No, TransMedics Group, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
BRKR
Bruker Corporation
$46.48
Mkt Cap: $7.1B
GKOS
Glaukos Corporation
$116.22
Mkt Cap: $6.7B
HNGE
Hinge Health, Inc.
$47.25
Mkt Cap: $3.7B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
INDV
Indivior PLC
$35.21
Mkt Cap: $4.4B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
OPCH
Option Care Health, Inc.
$32.51
Mkt Cap: $5.4B
OSCR
Oscar Health, Inc.
$14.90
Mkt Cap: $3.8B
Explore stocks similar to TMDX for comparison